Research
Hormonal
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide potent weight reduction among persons with overweight/obesity and show cardiovascular benefits.
GLP-1 RAs may be considered as a therapeutic option for weight management in patients with HIV and obesity.
StrongSupportsmedium confidence
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are well recognized to provide potent weight reduction among persons with overweight/obesity; in addition, studies have shown cardiovascular benefit among those with established cardiovascular disease.
Why this rating
The claim is based on a review of existing studies.
Source
Weighing In: Glucagon-Like Peptide-1 Receptor Agonism for Persons With HIV.
Teressa S Thomas et al. · PubMed · 2024
reviewCited 1×
Read the paper More from this paper
- Weight gain among persons with HIV on contemporary antiretroviral therapy can lead to overweight/obesity in the first 1 to 2 years, resulting in enhanced cardiometabolic risk.Strong
- Weight reduction starting at 5% body weight confers metabolic protection, such as improved hypertension and dysglycemia.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →